InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.270 0.01 (0.79%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 Application for quotation of securities - OSL 28 Mar 2024 4:02PM $0.005 $1.270 risen by 25,300%
$39 Prospectus - Entitlement Offer 25 Mar 2024 8:54AM $0.006 $1.270 risen by 21,066.67%
$39 Update - Proposed issue of securities - OSL 22 Mar 2024 2:50PM $0.007 $1.270 risen by 18,042.86%
$39 Placement and Entitlement Offer - amended timetable 22 Mar 2024 2:32PM $0.007 $1.270 risen by 18,042.86%
$39 Update - Proposed issue of securities - OSL 22 Mar 2024 8:20AM $0.007 $1.270 risen by 18,042.86%
$39 Placement and Entitlement Offer - addendum 21 Mar 2024 9:32AM $0.007 $1.270 risen by 18,042.86%
$39 Investor Presentation 20 Mar 2024 10:28AM $0.008 $1.270 risen by 15,775%
$39 Proposed issue of securities - OSL 20 Mar 2024 10:20AM $0.008 $1.270 risen by 15,775%
$39 Proposed issue of securities - OSL 20 Mar 2024 10:20AM $0.008 $1.270 risen by 15,775%
$39 Proposed issue of securities - OSL 20 Mar 2024 10:20AM $0.008 $1.270 risen by 15,775%
$39 Placement and Entitlement Offer to raise up to $7.1 million 20 Mar 2024 10:20AM $0.008 $1.270 risen by 15,775%
$39 Trading Halt 18 Mar 2024 9:46AM $0.008 $1.270 risen by 15,775%
$39 Appendix 4D and Half Year Accounts 28 Feb 2024 5:22PM $0.008 $1.270 risen by 15,775%
$39 OncoSil signs distribution agreement for Turkish market 1 Feb 2024 10:11AM $0.007 $1.270 risen by 18,042.86%
$39 84 German hospitals can negotiate fee for Oncosil device 1 Feb 2024 10:10AM $0.007 $1.270 risen by 18,042.86%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 11:30AM $0.007 $1.270 risen by 18,042.86%
$39 Change of Director's Interest Notice DC NL GL 20 Dec 2023 3:26PM $0.009 $1.270 risen by 14,841.18%
$39 Notification regarding unquoted securities - OSL 19 Dec 2023 5:02PM $0.009 $1.270 risen by 14,841.18%
$39 Notification regarding unquoted securities - OSL 19 Dec 2023 4:39PM $0.009 $1.270 risen by 14,841.18%
$39 Proposed issue of securities - OSL 18 Dec 2023 5:18PM $0.008 $1.270 risen by 15,775%
$39 Notification of cessation of securities - OSL 18 Dec 2023 4:46PM $0.008 $1.270 risen by 15,775%
$39 OncoSil receives $1.1m R&D tax incentive 15 Dec 2023 9:59AM $0.008 $1.270 risen by 15,775%
$39 First two commercial patient treatments in Greece 8 Dec 2023 8:19AM $0.008 $1.270 risen by 15,775%
$39 Notification of cessation of securities - OSL 6 Dec 2023 10:50AM $0.009 $1.270 risen by 14,011.11%
$39 Final Director's Interest Notice BL 5 Dec 2023 4:32PM $0.009 $1.270 risen by 14,011.11%

276 - 300 of 791 results

Page 12 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.